- CannPal is presenting at the 2019 Asian Hemp Industry Investment Summit at the Kerry Hotel in Hong Kong on June 28th 2019
- Managing Director, Layton Mills, will be presenting on the Company’s progress and the opportunity for cannabinoids in the animal health market in Asia
- Mr Mills’s presentation is attached to this release.
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to attach a presentation that will be delivered by CannPal Managing Director, Mr Layton Mills, at the 2019 Asian Hemp Industry Investment Summit at the Kerry Hotel in Hong Kong on June 28th 2019.
The purpose of the summit is to bring together cannabis industry leaders from all over the world, including expert groups on cannabis legislation in various countries, investment groups, and medical scientific research experts, to support the development of the Asian cannabis industry.
The forum is being co-hosted by the CBDG-Cannabis Industrial Fund alongside Arcview Group. The Arcview Investor Network includes more than 600 accredited investors who have put more than US$190 million behind 175 companies since inception.
About CannPal Animal Therapeutics
CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovate therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.